Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Entinostat + Pembrolizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Entinostat||HDAC inhibitor SNDX-275|MS 275||HDAC Inhibitor 41||Entinostat (MS-275) inhibits HDAC activity, with selectivity towards HDAC1, 2, and 3, which results in increased histone acetylation, and potentially leads to decreased tumor cell proliferation and tumor growth (PMID: 19724929, PMID: 17383217, PMID: 32503469).|
|Pembrolizumab||Keytruda||MK-3475||Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 86||Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, CD274 (PD-L1)-expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, cervical cancer, and triple-negative breast cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib or lenvatinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, and in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-expressing (CPS>=1) cervical cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03978624||Phase II||Pembrolizumab Entinostat + Pembrolizumab||Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer||Recruiting||USA||0|
|NCT03765229||Phase II||Entinostat + Pembrolizumab||An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma||Recruiting||USA||0|
|NCT03179930||Phase II||Entinostat + Pembrolizumab||Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas||Recruiting||USA||0|
|NCT02437136||Phase Ib/II||Entinostat + Pembrolizumab||Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma||Active, not recruiting||USA||0|
|NCT02936752||Phase I||Entinostat + Pembrolizumab||Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure||Active, not recruiting||USA||0|
|NCT02909452||Phase I||Entinostat + Pembrolizumab||Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors||Completed||USA||0|